In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method
- PMID: 2998812
- DOI: 10.1016/0014-2999(85)90379-6
In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method
Abstract
The relative in vivo receptor affinities of three oripavine drugs given subcutaneously were determined at the mu, delta and kappa type of opiate binding sites in rat brain. The oripavines include the agonist etorphine, the antagonist diprenorphine and the mixed agonist-antagonist buprenorphine. With the use of mu, delta and kappa specific labeling conditions in brain homogenates immediately after sacrifice (ex vivo labeling), the method relies on the assay of those receptor sites that remain unbound in vivo. Because of the slow receptor binding kinetics of the oripavines, little or no dissociation of the in vivo ligand occurs during the ex vivo labeling period. All three drugs displayed lower affinity in vivo at the delta sites relative to mu sites, whereas the kappa affinities were highly variable. Etorphine displayed considerable mu selectivity, while burpenorphine's affinity at the mu and kappa sites was similar. The apparent in vivo binding affinities obtained from the ex vivo labeling approach are compatible with previous results where tracers were applied in vivo. The dramatic differences of the in vivo and in vitro opiate receptor binding properties of the oripavines demonstrate the need for in vivo receptor binding parameters in the analysis of the function of individual receptor types.
Similar articles
-
Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.Eur J Pharmacol. 1999 Aug 13;378(3):323-30. doi: 10.1016/s0014-2999(99)00460-4. Eur J Pharmacol. 1999. PMID: 10493109
-
Buprenorphine: differential interaction with opiate receptor subtypes in vivo.J Pharmacol Exp Ther. 1982 Oct;223(1):157-62. J Pharmacol Exp Ther. 1982. PMID: 6288917
-
In vivo characterization of four types of opioid binding sites in rat brain.Life Sci. 1983;33 Suppl 1:187-9. doi: 10.1016/0024-3205(83)90474-5. Life Sci. 1983. PMID: 6141486
-
The orvinols and related opioids--high affinity ligands with diverse efficacy profiles.Curr Pharm Des. 2004;10(7):717-32. doi: 10.2174/1381612043453027. Curr Pharm Des. 2004. PMID: 15032698 Review.
-
Buprenorphine.Drug Alcohol Depend. 1985 Feb;14(3-4):363-72. doi: 10.1016/0376-8716(85)90067-5. Drug Alcohol Depend. 1985. PMID: 2986930 Review.
Cited by
-
Investigation of the antinociceptive activity of buprenorphine in sheep.Br J Pharmacol. 1987 Nov;92(3):527-33. doi: 10.1111/j.1476-5381.1987.tb11353.x. Br J Pharmacol. 1987. PMID: 3427266 Free PMC article.
-
Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.J Neurosci. 2009 Jun 3;29(22):7341-8. doi: 10.1523/JNEUROSCI.3723-08.2009. J Neurosci. 2009. PMID: 19494155 Free PMC article.
-
Investigation of the opioid system in absence seizures with positron emission tomography.J Neurol Neurosurg Psychiatry. 1993 Dec;56(12):1295-302. doi: 10.1136/jnnp.56.12.1295. J Neurol Neurosurg Psychiatry. 1993. PMID: 8270930 Free PMC article.
-
Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.CNS Drug Rev. 2002 Winter;8(4):377-90. doi: 10.1111/j.1527-3458.2002.tb00235.x. CNS Drug Rev. 2002. PMID: 12481193 Free PMC article. Review.
-
Opioid receptors and myocardial protection: do opioid agonists possess cardioprotective effects?Clin Drug Investig. 1998;15(5):445-54. doi: 10.2165/00044011-199815050-00009. Clin Drug Investig. 1998. PMID: 18370500
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials